10/08/2025
ANNOUNCING: Clinical Trial Opportunity for Patients with IgA Nephropathy (IgAN)
We’re excited to share a potential opportunity for our patients diagnosed with IgA Nephropathy to participate in a new clinical trial led by Takeda Pharmaceuticals.
This study is designed to evaluate a medication called Mezagitamab, which is being researched for its ability to preserve kidney function and target the underlying mechanisms of IgAN, not just the symptoms.
Here’s what you need to know:
✅ What is it?
A randomized, double-blind, placebo-controlled trial—which means neither you nor the research team will know whether you’re receiving Mezagitamab or a placebo. However, there's a 2:1 chance you'll be placed in the Mezagitamab group.
🕐 How long is the study?
- The study lasts about 104 weeks (or 2 years), divided into two 52-week cycles. Each cycle includes:
- 22 weeks of dosing (2 subcutaneous injections per visit, 16 doses total)
- 30 weeks of follow-up with no injections
💵 Compensation:
- Participants will receive $60 per visit.
👥 Who can participate? To qualify, you must:
- Be 18 or older
- Have biopsy-confirmed IgAN within the past 10 years
- Be on stable RAAS therapy
- Not have an active infection, recent major surgery (within 3 months), or a history of COPD or asthma
Interested?
We’d love to talk more with you! If you have any questions, you can get in touch with one of our research team members by calling our office. Alternatively, you can reach out to Sena Ostwalt, the lead for this study, at (612) 965-1922 to learn more or see if you qualify.
As always, our goal is to help advance kidney care while supporting you with the latest research opportunities. Please don’t hesitate to reach out with questions. 💚
